This tracker provides information on accelerated assessment requests for planned marketing authorization applications (MAAs) that have come before the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for a decision. It also tracks whether companies retain fast-track status for MAAs as they make their way through the EU centralized drug evaluation procedure.
This latest update (see table at the end of this article) reflects recent developments. Specifically, it records the fact that teclistamab, an investigational monoclonal antibody under development at Johnson &...
